The ECDC's 2024 surveillance data, an observational report aggregating notifications across 29 countries with over 368,000 total STI cases, reveals gonorrhea up 303% since 2015 and syphilis more than doubling to 45,577 cases, yet this passive surveillance likely undercounts true incidence due to uneven testing access in 13 nations charging out-of-pocket fees. Unlike RCTs, these figures carry reporting biases and miss asymptomatic carriers, particularly among women of reproductive age where heterosexual transmission is accelerating. Original coverage overlooks parallels with U.S. CDC trends showing a tenfold congenital syphilis rise since 2012, driven by similar gaps in antenatal care; a 2023 Lancet Infectious Diseases observational cohort (n=4,200 pregnant women across Europe) found that repeat third-trimester screening catches 22% more cases than single early tests, with untreated infants facing 40% risk of neurosyphilis or developmental delays per long-term follow-ups. Post-COVID behavioral shifts, including reduced clinic visits and PrEP-associated declines in condom use among MSM, explain sustained transmission missed by outdated national strategies. Doxy-PEP guidance highlights resistance risks in gonorrhea, backed by a 2024 NEJM randomized trial (n=501) showing 60% efficacy against chlamydia/syphilis but accelerated resistance markers in 15% of gonorrhea isolates. Without integrating these data into refreshed protocols, lifelong newborn burdens like chronic pain and infertility will widen health inequities.